CLINICAL TRIALS

Liver / Hepatocellular Carcinoma Clinical Trials in Wisconsin

10+ recruiting Liver / Hepatocellular Carcinoma trials in Wisconsin, sourced from ClinicalTrials.gov.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

RECRUITINGPhase 1

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

NCT05919264 · Madison
RECRUITING

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) prog

NCT03452774 · Milwaukee
ACTIVE NOT RECRUITINGPhase 1

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy)

NCT05120271 · Milwaukee
RECRUITINGPhase 2

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be remo

NCT05168163 · Milwaukee
ACTIVE NOT RECRUITING

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world

NCT02954094 · Madison
ACTIVE NOT RECRUITINGPhase 2

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Caboz

NCT02867592 · La Crosse
ACTIVE NOT RECRUITINGPhase 2

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participa

NCT06040099 · Milwaukee
ACTIVE NOT RECRUITINGPhase 2

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell g

NCT05194293 · Milwaukee
ACTIVE NOT RECRUITING

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.

NCT05064553 · Madison
RECRUITINGPhase 1

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myel

NCT06582017 · Milwaukee

RECOMMENDED RESOURCES FOR LIVER / HEPATOCELLULAR CARCINOMA

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
💼

eHealth Insurance

Licensed Agents

Shop ACA health plans from top insurers. Licensed agents help you find coverage that works with clinical trial participation — at no cost to you.

Compare Plans Free →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Liver / Hepatocellular Carcinoma clinical trials in Wisconsin?

Yes. Clinicals AI lists 10+ recruiting Liver / Hepatocellular Carcinoma trials in Wisconsin sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Liver / Hepatocellular Carcinoma trial in Wisconsin?

Eligibility varies by study. Most trials require a confirmed Liver / Hepatocellular Carcinoma diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Liver / Hepatocellular Carcinoma clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.